1. Home
  2. LKFT vs HROW Comparison

LKFT vs HROW Comparison

Compare LKFT & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakefront Biotherapeutics American Depositary Shares

LKFT

Lakefront Biotherapeutics American Depositary Shares

N/A

Current Price

$29.01

Market Cap

2.0B

Sector

Health Care

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$30.75

Market Cap

1.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LKFT
HROW
Founded
1999
1998
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2007
2008

Fundamental Metrics

Financial Performance
Metric
LKFT
HROW
Price
$29.01
$30.75
Analyst Decision
Hold
Strong Buy
Analyst Count
6
9
Target Price
$30.65
★ $65.00
AVG Volume (30 Days)
287.6K
★ 486.5K
Earning Date
11-11-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 71.43
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$28.81
Revenue Next Year
N/A
$53.97
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.68
$28.54
52 Week High
$32.41
$54.98

Technical Indicators

Market Signals
Indicator
LKFT
HROW
Relative Strength Index (RSI) 54.78 27.10
Support Level $26.15 $28.54
Resistance Level $30.35 $35.43
Average True Range (ATR) 0.87 1.25
MACD 0.09 -0.21
Stochastic Oscillator 50.35 11.48

Price Performance

Historical Comparison
LKFT
HROW

About LKFT Lakefront Biotherapeutics American Depositary Shares

Lakefront Biotherapeutics NV a biopharmaceutical company committed to improving the lives of people with severe diseases. It focuses on delivering medicines with transformational impact for patients by accelerating life-changing science and innovation in areas of high unmet need. Its pipelines includes GLPG3667, GLPG5101, and GLPG5301.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: